Impact factors (IFs) are published each year by Clarivate Analytics, a company providing multiple products related to scientific research insights. The IF reflects a journal’s performance and status through a record of how often its articles are cited in other biomedical journals. The release of IF data is eagerly awaited each year by publishers and editorial teams. The data released June 30 ranked journals with respect to 2020 citations of articles published during 2018–2019.

The IF for Pharmacotherapy has increased to 4.705. The increase from last year’s value of 3.473 launches Pharmacotherapy’s IF well over an important threshold of 4.0 and reaches an all-time high. This 35% increase can be put in a different perspective by understanding how Pharmacotherapy is ranked within its designated journal category, Pharmacy and Pharmacology. Last year, Pharmacotherapy ranked 83rd out of 270 journals. This year, Pharmacotherapy improved to a ranking of 74th out of 275 journals.

The IF should not be the sole measure of journal quality, but it remains a vital measure in biomedical publishing of a journal’s impact on its field. A journal’s citation metrics alongside data on downloads, international readership, and comparisons to other journals are all measures of a journal’s success.

The publication of Pharmacotherapy is made possible through the combined effort of many individuals, including publication staff, editors, editorial board members, and reviewers. Most important are the authors who choose to submit their best work to the journal.

The top 10 articles published in 2018–2019 with the most citations in 2020 are as follows:

1. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins.
2. Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017.
3. Turner RB, Kojiro K, Shephard EA, et al. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
4. Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of Exposure to Antipseudomonal ß-Lactam Antibiotics in the Critically Ill and Development of New Resistance.
5. Cook AM, Hatton-Kolpek J. Augmented Renal Clearance.
6. Veve MP, Wagner JL. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
7. Jorgensen SCJ, Rybak MJ. Meropenem and Vaborbactam: Stepping Up the Battle Against Carbapenem-Resistant Enterobacteriaceae.
8. Meng L, Wong T, Huang S, et al. Conversion from Vancomycin Trough Concentration–Guided Dosing to Area Under the Curve–Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
9. Flowers SA, Baxter NT, Ward KM, et al. Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia.
10. Shaeer KM, Zmarlicka MT, Chahine EB, Piccicacco N, Cho JC. Plazomicin: A Next-Generation Aminoglycoside.